Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Inventiva SA

Start price
Target price
Perf. (%)
€3.31
10.09.21
€12.00
-
10.09.21

Could be worthwhile Investment >10% per year
Inventiva SA

Start price
Target price
Perf. (%)
€3.31
10.09.21
€8.00
-
10.09.21

Could be worthwhile Investment >10% per year
Poxel S.A.

Start price
Target price
Perf. (%)
€6.46
06.09.21
€5.00
06.09.22
-9.30%
07.10.21

Could be worthwhile Investment >10% per year
buy
Innate Pharma

Start price
Target price
Perf. (%)
€4.80
05.09.21
-
05.09.22
-47.79%
07.03.22

Probably not worthwhile Investment
Innate Pharma

Start price
Target price
Perf. (%)
€6.20
03.09.21
-
03.09.22
-25.29%
06.09.21

Risky Investment
buy
Valneva SE

Start price
Target price
Perf. (%)
€20.18
03.09.21
€30.00
03.09.22
-59.38%
03.09.22

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Some uniques
Higher risks for its business
buy
Advicenne

Start price
Target price
Perf. (%)
€7.78
31.08.21
€10.00
30.05.22
-6.94%
17.10.21

Could be worthwhile Investment >10% per year
Advicenne

Start price
Target price
Perf. (%)
€1.97
31.08.21
€10.00
30.05.22
-
31.08.21

Could be worthwhile Investment >10% per year
buy
Valneva SE

Start price
Target price
Perf. (%)
€13.84
25.08.21
-
25.08.22
-32.23%
26.08.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Erytech Pharma S.A.

Start price
Target price
Perf. (%)
€5.10
30.07.21
-
30.07.22
2.55%
08.08.21

Risky Investment
buy
Valneva SE

Start price
Target price
Perf. (%)
€11.24
20.07.21
€20.00
20.07.22
116.90%
25.11.21

Could be worthwhile Investment >10% per year
Very valuable balance sheet
buy
Valneva SE

Start price
Target price
Perf. (%)
€11.85
08.07.21
-
08.07.22
-11.18%
08.07.22

buy
Sanofi S.A.

Start price
Target price
Perf. (%)
€86.85
08.07.21
€115.00
08.07.22
13.32%
08.07.22

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Future proof or reliable business model
buy
Sanofi S.A.

Start price
Target price
Perf. (%)
€86.85
08.07.21
€115.00
08.07.22
13.32%
08.07.22

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Future proof or reliable business model
buy
Sanofi S.A.

Start price
Target price
Perf. (%)
€86.85
08.07.21
€115.00
08.07.22
13.32%
08.07.22

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Future proof or reliable business model
Abivax S.A.

Start price
Target price
Perf. (%)
€30.50
28.06.21
€25.00
28.06.22
-16.39%
01.12.21

Future proof or reliable business model
Probably not worthwhile Investment
overvalued
Very low/no dividend yield expected
Valneva SE

Start price
Target price
Perf. (%)
€10.89
17.06.21
€8.00
17.06.22
3.21%
20.07.21

Could be worthwhile Investment >10% per year
Very valuable balance sheet
buy
Advicenne

Start price
Target price
Perf. (%)
€8.74
30.05.21
€10.00
30.05.22
-10.98%
31.08.21

Could be worthwhile Investment >10% per year
Virbac S.A.

Start price
Target price
Perf. (%)
€275.00
28.04.21
€270.00
28.04.22
43.82%
25.10.21

Could be worthwhile Investment >10% per year
Boiron S.A.

Start price
Target price
Perf. (%)
€38.55
13.04.21
€36.00
13.04.22
-1.30%
26.11.21

Could be worthwhile Investment >10% per year
buy
Advicenne

Start price
Target price
Perf. (%)
€13.60
14.02.21
€14.00
14.02.22
-35.74%
30.05.21

Could be worthwhile Investment >10% per year
DBV Technologies S.A.

Start price
Target price
Perf. (%)
€8.16
15.01.21
-
15.01.22
-63.58%
16.01.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
buy
Adocia

Start price
Target price
Perf. (%)
€7.54
16.11.20
€10.00
16.11.21
18.04%
17.11.21

Could be worthwhile Investment >10% per year
Future proof or reliable business model
buy
Innate Pharma

Start price
Target price
Perf. (%)
€4.10
15.11.20
€5.50
15.11.21
7.86%
16.11.21

Could be worthwhile Investment >10% per year
buy
DBV Technologies S.A.

Start price
Target price
Perf. (%)
€3.45
03.11.20
-
04.11.21
136.51%
15.01.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group